Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies.

ABSTRACT:

Background

Antibody-drug conjugates (ADCs) play an important role in the targeted therapy of gynecological malignancies. The purpose of this study was to investigate the expression of targets in gynecologic malignancies in order to predict the selection of targets for the development of antibody-drug conjugates.

Methods

In this article, we identified existing ADCs and their targets through clinical trial databases and public genomic datasets, performed differential analysis of tumor antigen targets (TATs) expression between tumor and normal tissues, and evaluated the necessity of the targets for tumor cell lines.

Results

In gynecologic malignancies, we have identified several highly expressed TATs, some of which have been targeted by FDA-approved ADCs, such as TROP2 a

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC11880013 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature